CCM
PBYI icon

Consonance Capital Management’s Puma Biotechnology PBYI Stock Holding History

Consonance Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,303,455
Closed -$106M – 26
2018
Q3 		$106M Buy
2,303,455
+214,338
+10% +$10.3M 5.69% 4
2018
Q2 		$124M Buy
+2,089,117
New +$121M 7.97% 2

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Consonance Capital Management's PBYI Position: Q4 2018 in Review

Consonance Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 2,303,455 shares — an estimated $106M sold.

Consonance Capital Management first reported a position in PBYI in Q2 2018 and held it in 2 quarters. The position peaked at $124M in Q2 2018. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

  • Consonance Capital Management reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Consonance Capital Management sold 2,303,455 Puma Biotechnology shares in Q4 2018, an estimated $106M.
  • Consonance Capital Management first reported a position in Puma Biotechnology in Q2 2018 and held it in 2 quarters.
  • Consonance Capital Management's Puma Biotechnology position peaked at $124M in Q2 2018.
  • 141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on Consonance Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.